2022-11-15T13:53:25-06:00 2021-12-31 390859910 BAKER TILLY US LLP 1570 FRUITVILLE PIKE SUITE 400 LANCASTER PA 17601 990 2021-01-01 521906152 PARENTERAL DRUG ASSOCIATION INC PARE 3016565900 4350 EAST WEST HIGHWAY 200 BETHESDA MD 20814 JENNIFER BELL CHIEF FINANCIAL OFFICER 3016565900 2022-11-15 1 JENNIFER BELL 999009999 KERRI N BOGDA CPA P00760402 7177404863 2022-11-15 X 0 AAL1 IAL1 2021 2022-09-23 18:48:47Z RICHARD JOHNSON 4350 EAST WEST HIGHWAY 200 BETHESDA MD 20814 10636020 0 X WWW.PDA.ORG X 1994 DC TO BE THE FOREMOST GLOBAL PROVIDER OF SCIENCE, TECHNOLOGY AND REGULATORY INFORMATION AND EDUCATION FOR THE PHARMACEUTICAL AND BIOPHARMACEUTICAL COMMUNITY. 17 17 46 1821 270496 0 77140 93962 6308209 6126737 173698 530227 1188376 1293847 7747423 8044773 0 854 0 0 5064751 5351978 0 0 0 4438265 5194434 9503016 10547266 -1755593 -2502493 13130551 14078226 6992554 9631645 6137997 4446581 X TO DEVELOP SCIENTIFICALLY SOUND, PRACTICAL TECHNICAL INFORMATION AND RESOURCES TO ADVANCE SCIENCE AND REGULATION FOR THE PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY THROUGH THE EXPERTISE OF OUR GLOBAL MEMBERSHIP. 0 0 PROGRAMS & MEETINGS-EDUCATE MEMBERS AND NON-MEMBERS BY TEACHING DEVELOPMENTS IN MANUFACTURING AND QUALITY CONTROL FOR PRIMARY STERILE PRODUCT DEVELOPMENTS. TRAINING & RESEARCH INSTITUE (TRI)EDUCATIONAL COURSES - TECHNICAL TRAINING FOR SCIENTISTS IN THE PHARMACEUTICAL AREAS OF MANUFACTURING, DEVELOPMENT AND QUALITY CONTROL. TRAINING - TRAIN MEMBERS AND NON-MEMBERS TO BASIC MANUFACTURING TECHNIQUES CENTERED AROUND GMP GUIDELINES. MEMBERSHIP & CHAPTER SERVICES-PROVIDE THE LATEST GUIDELINES FOCUSING ON TECHNOLOGY INFORMATION ON MANUFACTURING, TECHNICAL REPORTS, AND QUALITY CONTROL. PUBLICATION SALES- PROVIDE THE LATEST SCIENCE, TECHNOLOGY AND REGULATORY INFORMATION.SALES, EXHIBIT & SPONSORSHIP, ADVERTISING- PROVIDE THE LATEST SCIENCE, TECHNOLOGY AND REGULATORY INFORMATION 0 1 0 1 0 0 0 0 0 1 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 1 1 1 0 1 60 0 46 1 1 1 0 0 0 1 1 0 0 0 X 17 17 0 0 0 0 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 0 MD X JENNIFER BELL CFO 3016565900 4350 EAST WEST HIGHWAY STE 200 BETHESDA MD 20814 JETTE CHRISTENSEN CHAIR 1.00 1.00 X X 0 0 0 SUSAN SCHNIEPP CHAIR-ELECT 1.00 1.00 X 0 0 0 EMMA RAMNARINE SECRETARY 1.00 1.00 X X 0 0 0 MELISSA SEYMOUR MBA TREASURER 1.00 1.00 X X 0 0 0 REBECCA DEVINE PHD IMMEDIATE PAST CHAIR 1.00 1.00 X 0 0 0 BARBARA ALLEN PHD DIRECTOR 1.00 1.00 X 0 0 0 MICHAEL BLACKTON DIRECTOR 1.00 1.00 X 0 0 0 BETTINE BOLTRES PHD DIRECTOR 1.00 1.00 X 0 0 0 TIA BUSH DIRECTOR 1.00 1.00 X 0 0 0 JAVIER CAMPOSANO DIRECTOR 1.00 1.00 X 0 0 0 GHADA HADDAD DIRECTOR 1.00 1.00 X 0 0 0 JOYCE HANSEN DIRECTOR 1.00 1.00 X 0 0 0 STEPHAN KRAUSE PHD DIRECTOR 1.00 1.00 X 0 0 0 MARY OATES DIRECTOR 1.00 1.00 X 0 0 0 MATHIAS ROMACKER DIRECTOR 1.00 1.00 X 0 0 0 ANIL SAWANT PHD DIRECTOR 1.00 1.00 X 0 0 0 OSAMU SKIROKIZAWA DIRECTOR 1.00 1.00 X 0 0 0 RICHARD JOHNSON PRESIDENT, CEO 37.50 1.00 X 395032 0 56516 GLENN WRIGHT COO 37.50 0.00 X 255394 0 39470 DAVID HALL VP, EXHIBITS 37.50 0.00 X 180077 0 46788 DEBBIE GOLDSTEIN VP, MARKETING 37.50 0.00 X 165752 0 43469 JENNIFER BELL VP, FINANCE 37.50 0.00 X 165593 0 44132 DAVID TALMAGE VP, EDUCATION 37.50 0.00 X 158067 0 49566 MOLLY O'NEILL VP, PROGRAMS 37.50 0.00 X 148791 0 42072 WALTER MORRIS DIRECTOR, PUBLISHING 37.50 0.00 X 127089 0 31828 JOSHUA EATON DIRECTOR, SRA 37.50 0.00 X 105853 0 29302 FARAMARZ KOLIVAND SR. WEB MASTER 37.50 0.00 X 106146 0 22125 JAHANVI MILLER DIRECTOR, SRA 37.50 0.00 X 105519 0 14942 1913313 0 420210 14 0 1 0 MULTIMEDIA PHARMA SCIENCES LLC 2 CLARKE DRIVE SUITE 100 CRANBURY NJ 08512 ADVERTISING 265450 RSM US LLP 331 WEST 3RD STREET STE 200 DAVENPORT IA 52801 IT CONSULTING & AUDITING SERVICES 259115 2 93962 83962 93962 MEETINGS, EXHIBITS, & CONFERENCES 541900 2108570 2108570 MEMBERSHIP DUES 900099 2063618 2063618 EDUCATION 541900 1812475 1812475 JOURNAL SUBSCRIPTION 900099 142074 142074 6126737 175196 175196 115601 115601 2790424 2435393 355031 355031 355031 777462 155854 621608 621608 ADVERTISING 541800 270496 270496 FORFEITURES 900099 159562 159562 CANCELLATION FEES 900099 74605 74605 51975 51975 556638 8044773 6748345 270496 931970 X 854 1599856 2856776 190029 425946 279371 13106 46288 67695 1278585 590839 455389 113349 1115880 96641 755315 440903 75590 EVENT EXPENSES 73734 DUES AND SUBSCRIPTIONS 44808 TRAINING AND RECRUITING 19216 BAD DEBTS 7065 31 10547266 267537 170505 236225 705468 236190 365320 44894 41854 255186 153029 7968320 5488244 2771991 2480076 8860862 9629918 457666 532056 13130551 14078226 1965151 2054552 1286405 1495839 1866496 3695967 1874502 2385287 6992554 9631645 X 6137997 4446581 6137997 4446581 13130551 14078226 -2502493 811077 0 X 0 1 X 1 0 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 4069788 2669303 1400485 3033146 2818941 214205 865386 865386 2480076 DEFERRED RENT 2360588 DUE TO CHAPTERS 24699 2385287 9024704 811077 13000 824077 8200627 -155854 -155854 8044773 10716120 13000 155854 168854 10547266 0 10547266 PART XI, LINE 4B - OTHER ADJUSTMENTS: COST OF GOODS SOLD -155,854. PART XII, LINE 2D - OTHER ADJUSTMENTS: COST OF GOODS SOLD 155,854. X 1 1 X X X 0 0 0 RICHARD JOHNSON PRESIDENT, CEO 387439 0 0 0 7593 0 41568 0 14948 0 451548 0 0 0 GLENN WRIGHT COO 255394 0 0 0 0 0 38500 0 970 0 294864 0 0 0 DAVID HALL VP, EXHIBITS 180077 0 0 0 0 0 32020 0 14768 0 226865 0 0 0 JENNIFER BELL VP, FINANCE 165593 0 0 0 0 0 29236 0 14896 0 209725 0 0 0 DEBBIE GOLDSTEIN VP, MARKETING 165752 0 0 0 0 0 29129 0 14340 0 209221 0 0 0 DAVID TALMAGE VP, EDUCATION 158067 0 0 0 0 0 28220 0 21346 0 207633 0 0 0 MOLLY O'NEILL VP, PROGRAMS 148791 0 0 0 0 0 27486 0 14586 0 190863 0 0 0 WALTER MORRIS DIRECTOR, PUBLISHING 127089 0 0 0 0 0 17368 0 14460 0 158917 0 0 0 PART I, LIN 1A: PDA PAYS 80% OF THE COST FOR USE OF A HEALTH CLUB (GYM) FOR ALL OF ITS EMPLOYEES. X LABORATORY SUPPLIES 3 71237 COMPARABLE SALES 0 0 1 0 PART I, COLUMN (B): THE NUMBER REPORTED IN PART I, COLUMN B REPRESENTS THE NUMBER OF CONTRIBUTORS. FORM 990, PART VI, SECTION A, LINE 1A THE EXECUTIVE COMMITTEE CONSISTS OF THE ELECTED OFFICERS, IMMEDIATE PAST CHAIRMAN, AND PRESIDENT. IT SHALL ACT ON BEHALF OF THE BOARD OF DIRECTORS IN THE OPERATION OF THE ASSOCIATION AND SHALL HAVE SUCH AUTHORITY AS MAY BE ESTABLISHED FROM TIME TO TIME BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION A, LINE 6 THE ASSOCIATION HAS INDIVIDUAL MEMBERS. THE ASSOCIATION DOES NOT HAVE ANY STOCK HOLDERS. FORM 990, PART VI, SECTION A, LINE 7A PDA'S GLOBAL MEMBERSHIP IS ELIGIBLE TO VOTE TO ELECT PDA'S BOARD OF DIRECTORS. THE PROCESS IS AS FOLLOWS: A NOMINATING COMMITTEE, CONSISTING OF THE CHAIRMAN, CHAIRMAN-ELECT, AND IMMEDIATE PAST CHAIRMAN, SUBMITS TO THE BOARD OF DIRECTORS A SLATE WITH (2) NOMINATED CANDIDATES FOR EACH OFFICER POSITION AND (2) NOMINATED CANDIDATES FOR EACH ELECTED DIRECTOR POSITION. THE BOARD OF DIRECTORS, THEN VOTES TO SELECT 1 CANDIDATE FOR EACH OPEN OFFICER POSITION AND 2 FOR DIRECTORS TO SEND TO THE FULL MEMBERSHIP FOR VOTING. AN ELECTRONIC BALLOT CONTAINING THE NAMES OF ALL CANDIDATES FOR ELECTION, WITH PROVISION FOR A "WRITE-IN" CANDIDATE FOR EACH POSITION TO BE FILLED, IS THEN PROVIDED TO EACH ASSOCIATION MEMBER ENTITLED TO VOTE. FORM 990, PART VI, SECTION A, LINE 7B BYLAWS AMENDMENT PROCESS: EACH PROPOSED AMENDMENT OF PDA'S BYLAWS, APPROVED BY VOTE OF AT LEAST TWELVE (12) DIRECTORS, SHALL BE SUBMITTED WITH A BALLOT TO ALL PDA MEMBERS ENTITLED TO VOTE. A PROPOSED BYLAWS AMENDMENT SHALL BECOME EFFECTIVE UPON RECEIVING A TWO-THIRDS (2/3) "YES" VOTE OF THE MEMBER BALLOTS RECEIVED. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS REVIEWED BY THE PRESIDENT AND EXECUTIVE COMMITTEE MEMBERS. THE FORM 990, IN PDF FILE FORMAT, IS THEN PROVIDED TO THE FULL GOVERNING BODY (BOARD OF DIRECTORS) PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C FROM PDA'S CONFLICT OF INTEREST POLICY: 1. DUTY TO DISCLOSE IN CONNECTION WITH ANY ACTUAL OR POSSIBLE CONFLICT OF INTEREST, AN INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF THE FINANCIAL INTEREST AND BE GIVEN THE OPPORTUNITY TO DISCLOSE ALL MATERIAL FACTS TO THE DIRECTORS AND MEMBERS OF THE COMMITTEES WITH GOVERNING BOARD DELEGATED POWERS CONSIDERING THE PROPOSED TRANSACTION OR ARRANGEMENT. 2. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND ALL MATERIAL FACTS, AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, HE/SHE SHALL LEAVE THE GOVERNING BOARD OR COMMITTEE MEETING WHILE THE DETERMINATION OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR COMMITTEE MEMBERS SHALL DECIDE IF A CONFLICT OF INTEREST EXISTS. 3. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST A. AN INTERESTED PERSON MAY MAKE A PRESENTATION AT THE GOVERNING BOARD OR COMMITTEE MEETING, BUT AFTER THE PRESENTATION, HE/SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE TRANSACTION OR ARRANGEMENT INVOLVING THE POSSIBLE CONFLICT OF INTEREST. B. THE CHAIRPERSON OF THE GOVERNING BOARD OR COMMITTEE SHALL, IF APPROPIATE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. C. AFTER EXERCISING DUE DILIGENCE, THE GOVERNING BOARD OR COMMITTEE SHALL DETERMINE WHETHER PDA CAN OBTAIN WITH REASONABLE EFFORTS A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. D. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY POSSIBLE UNDER CIRCUMSTANCES NOT PRODUCING A CONFLICT OF INTEREST, THE GOVERNING BOARD OR COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN PDA'S BEST INTEREST, FOR ITS OWN BENEFIT, AND WHETHER IT IS FAIR AND REASONABLE. IN CONFORMITY WITH THE ABOVE DETERMINATION IT SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT. 4. VIOLATIONS OF THE CONFLICT OF INTEREST POLICY A. IF THE GOVERNING BOARD OR COMMITTEE HAS REASONABLE CAUSE TO BELIEVE A MEMBER HAS FAILED TO DISCLOSE ACTUAL OR POSSIBLE CONFLICTS OF INTEREST, IT SHALL INFORM THE MEMBER OF THE BASIS FOR SUCH BELIEF AND AFFORD THE MEMBER AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING THE MEMBER'S RESPONSE AND AFTER MAKING FURTHER INVESTIGATION AS WARRANTED BY THE CIRCUMSTANCES, THE GOVERNING BOARD OR COMMITTEE DETERMINES THE MEMBER HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. THE CONFLICT OF INTEREST POLICY DOES MENTION FAMILY AND BUSINESS RELATIONSHIPS AS A SOURCE FOR POTENTIAL CONFLICTS. FORM 990, PART VI, SECTION B, LINE 15 THE ASSOCIATION USES THE FOLLOWING METHODS TO DETERMINE THE COMPENSATION OF THE PRESIDENT/CEO AND OTHER KEY EMPLOYEES: COMPENSATION COMMITTEES, COMPENSATION STUDY OR SURVEY, AND APPROVAL BY THE BOARD OR COMPENSATION COMMITTEE. THESE METHODS ARE USED TO ENSURE COMPENSATION IN WITHIN FAIR MARKET VALUE RANGE FOR THE INDUSTRY. FORM 990, PART VI, SECTION C, LINE 19 ASSOCIATION BYLAWS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE MAINTAINED AND AVAILABLE TO THE ASSOCIATION'S GOVERNING BODIES AND MEMBERS. FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G CONTRACT RESOURCES 1,160,908. TEMPORARY HELP 117,677. FOUNDATION FOR PHARMACEUTICAL EDUCATION TRAINING AND RESEARCH 4350 EAST WEST HWY STE 200 BETHESDA MD 20814 522075244 SUPPORT EDUCATION, TRAINING AND RESEARCH IN THE PHARMACEUTICAL DC 501(C)(3) LINE 12B, II PARENTERAL DRUG ASSOCIATION INC 1 PDA EUROPE GEMEINNUTZIGE GMBH AM BORSIGTURM 60 BERLIN GM 13507 SHARES PDA MISSION AS STATED ON PAGE 1 OF THIS FORM 990 GM NONPROFIT GERMAN PARENTERAL DRUG ASSOCIATION INC 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 PDA EUROPE GEMEINNUTZIGE GMBH D 242955 COST PART II, IDENTIFICATION OF RELATED TAX-EXEMPT ORGANIZATIONS: NAME OF RELATED ORGANIZATION: FOUNDATION FOR PHARMACEUTICAL EDUCATION, TRAINING AND RESEARCH PRIMARY ACTIVITY: SUPPORT EUDCATION, TRAINING AND RESEARCH IN THE PHARMACEUTICAL SCIENCES